Cargando…

Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience

OBJECTIVE: To assess the treatment options and associated complications in patients with May–Thurner’s syndrome (MTS). METHODS: We retrospectively reviewed the charts of patients diagnosed with MTS. Thorough review was completed and data relevant to methods of diagnosis, treatment, complications, ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Sigua-Arce, Priscilla, Mando, Ramy, Spencer, Lisa, Halalau, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384425/
https://www.ncbi.nlm.nih.gov/pubmed/34447265
http://dx.doi.org/10.2147/IJGM.S325231
_version_ 1783741911832461312
author Sigua-Arce, Priscilla
Mando, Ramy
Spencer, Lisa
Halalau, Alexandra
author_facet Sigua-Arce, Priscilla
Mando, Ramy
Spencer, Lisa
Halalau, Alexandra
author_sort Sigua-Arce, Priscilla
collection PubMed
description OBJECTIVE: To assess the treatment options and associated complications in patients with May–Thurner’s syndrome (MTS). METHODS: We retrospectively reviewed the charts of patients diagnosed with MTS. Thorough review was completed and data relevant to methods of diagnosis, treatment, complications, hospital readmission, and mortality were extracted from patient charts. The patients were followed for two years after diagnosis. RESULTS: Of the 47 patients identified as having “MTS”, 32 (70%) were diagnosed formally with either magnetic resonance venography, computed tomography venography, or ultrasound. Two patients were excluded for insufficient availability of follow-up records. Mean age of the population included (N = 30) was 50.24 ±15.33 years and 83% (N = 25) had female gender. The majority (40%) of patients were treated with anticoagulation, thrombolysis, and stent placement, and 13.3% received a combination of anticoagulation, antiplatelet agent, thrombolysis, and stent placement. Overall, we found 28 patients (93%) who underwent endovascular stenting. However, 39.3% (11/28) had stent-related complications that included stent thrombosis, stenosis, and migration. One patient underwent open heart surgery for stent retrieval. Duration of anticoagulation therapy ranged from 6 months to lifelong. Two patients (6.7%) suffered major bleeds requiring transfusion. Fourteen patients (46.6%) developed post-thrombotic syndrome. Seven (23.3%) patients required MTS-related readmission within 30 days. No mortality was noted at two-year follow-up. CONCLUSION: Although our study only included 30 patients, it was evident to us that there is no consensus in the management of MTS. Furthermore, endovascular stenting, which has a major role in the management of MTS, has complication rates that hover close to 40%. Further research is needed to help develop a standardized evidence-based approach in the management of MTS that ensures a decreased risk of immediate and long-term complications.
format Online
Article
Text
id pubmed-8384425
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83844252021-08-25 Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience Sigua-Arce, Priscilla Mando, Ramy Spencer, Lisa Halalau, Alexandra Int J Gen Med Original Research OBJECTIVE: To assess the treatment options and associated complications in patients with May–Thurner’s syndrome (MTS). METHODS: We retrospectively reviewed the charts of patients diagnosed with MTS. Thorough review was completed and data relevant to methods of diagnosis, treatment, complications, hospital readmission, and mortality were extracted from patient charts. The patients were followed for two years after diagnosis. RESULTS: Of the 47 patients identified as having “MTS”, 32 (70%) were diagnosed formally with either magnetic resonance venography, computed tomography venography, or ultrasound. Two patients were excluded for insufficient availability of follow-up records. Mean age of the population included (N = 30) was 50.24 ±15.33 years and 83% (N = 25) had female gender. The majority (40%) of patients were treated with anticoagulation, thrombolysis, and stent placement, and 13.3% received a combination of anticoagulation, antiplatelet agent, thrombolysis, and stent placement. Overall, we found 28 patients (93%) who underwent endovascular stenting. However, 39.3% (11/28) had stent-related complications that included stent thrombosis, stenosis, and migration. One patient underwent open heart surgery for stent retrieval. Duration of anticoagulation therapy ranged from 6 months to lifelong. Two patients (6.7%) suffered major bleeds requiring transfusion. Fourteen patients (46.6%) developed post-thrombotic syndrome. Seven (23.3%) patients required MTS-related readmission within 30 days. No mortality was noted at two-year follow-up. CONCLUSION: Although our study only included 30 patients, it was evident to us that there is no consensus in the management of MTS. Furthermore, endovascular stenting, which has a major role in the management of MTS, has complication rates that hover close to 40%. Further research is needed to help develop a standardized evidence-based approach in the management of MTS that ensures a decreased risk of immediate and long-term complications. Dove 2021-08-20 /pmc/articles/PMC8384425/ /pubmed/34447265 http://dx.doi.org/10.2147/IJGM.S325231 Text en © 2021 Sigua-Arce et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sigua-Arce, Priscilla
Mando, Ramy
Spencer, Lisa
Halalau, Alexandra
Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience
title Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience
title_full Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience
title_fullStr Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience
title_full_unstemmed Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience
title_short Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience
title_sort treatment of may–thurner’s syndrome and associated complications: a multicenter experience
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384425/
https://www.ncbi.nlm.nih.gov/pubmed/34447265
http://dx.doi.org/10.2147/IJGM.S325231
work_keys_str_mv AT siguaarcepriscilla treatmentofmaythurnerssyndromeandassociatedcomplicationsamulticenterexperience
AT mandoramy treatmentofmaythurnerssyndromeandassociatedcomplicationsamulticenterexperience
AT spencerlisa treatmentofmaythurnerssyndromeandassociatedcomplicationsamulticenterexperience
AT halalaualexandra treatmentofmaythurnerssyndromeandassociatedcomplicationsamulticenterexperience